



EAGLE
BIOSCIENCES

Insulin ELISA Assay Kit

Catalog Number:

INS31-K01 (1 x 96 wells)

For Research Use Only. Not for use in diagnostic procedures.

v. 2.2 (03.21.19)

EAGLE BIOSCIENCES, INC.
20A Northwest Blvd., Suite 112, Nashua, NH 03063
Phone: 617-419-2019 Fax: 617-419-1110
WWW.EAGLEBIO.COM



INTENDED USE

Eagle Biosciences human Insulin ELISA Assay Kit is intended for use in the quantitative determination of human insulin in serum and/or plasma. The EagleBio Insulin ELISA Assay kit is intended for research use only and not intended for diagnostic procedures.

ASSAY BACKGROUND

Insulin is a peptide hormone, produced by beta cells of the pancreas. Enzymatic cleavage of proinsulin results in the production of equimolar amounts of insulin and C-peptide in circulation. Insulin is central to regulating carbohydrate and fat metabolism in the body.

Excessive amounts of insulin are associated with excess amounts of glucose in the system. High levels of insulin are known to cause weight gain, water bloating, high blood pressure, magnesium deficiency and an increase in the amount of inflammatory compounds in the blood, which causes blood clots and blood vessel damage.

Insulin, when insufficiently produced, results in diabetes mellitus. In most cases, a high fasting insulin level is consistent with insulin resistance symptoms, but in some cases, it can be caused by more serious conditions such as Cushing's syndrome, acromegaly or possibly insulinoma.

PRINCIPLE OF THE ASSAY

This Insulin ELISA Assay Kit is designed, developed and produced for the quantitative measurement of human Insulin in serum and /or EDTA-plasma samples. The assay utilizes the "sandwich" technique with selected antibodies that bind to various epitopes of Insulin.

Assay standards, controls and patient samples are added directly to wells of a microplate that is coated with Insulin monoclonal antibody. Simultaneously, a horseradish peroxidase-conjugated Insulin specific antibody is added to each well. After the first incubation period, the antibody on the wall of microtiter well captures human Insulin in the sample and unbound proteins in each microtiter well are washed away. A "sandwich" of Insulin antibody --- human Insulin --- HRP conjugated tracer antibody" is formed. The unbound tracer antibody is removed in the subsequent washing step. For the detection of this immunocomplex, the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to human Insulin on the wall of the microtiter well is directly proportional to the amount of Insulin in the sample. A standard curve is generated by plotting the absorbance versus the respective human Insulin concentration for each standard on point-to-point or 4 parameter curve fit. The concentration of human Insulin in test samples is determined directly from this standard curve.



REAGENTS: Preparation and Storage

This Insulin ELISA Assay Kit must be stored at 2 – 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

Prior to use, allow all reagents to come to room temperature. Reagents of the Insulin ELISA Assay Kit from different kit lot numbers should not be combined or interchanged.

1. Insulin Antibody Coated Microplate

One microplate with 12 by 8 strips (96 wells total) coated with Insulin Monoclonal antibody. The plate is framed and sealed in a foil zipper bag with a desiccant. This reagent should be stored at 2 – 8 °C and is stable until the expiration date on the Insulin ELISA Assay Kit box.

2. Insulin Tracer Antibody

One vial containing 12 mL ready-to-use HRP-labeled Insulin antibody in a stabilized protein matrix. This reagent should be stored at 2 – 8°C. It is stable until the expiration date on the Insulin ELISA Assay Kit box.

3. ELISA Wash Concentrate

One bottle containing **30 mL** of 30-fold concentrate. Before use the contents must be diluted with **870 mL** of demineralized water and mixed well. Upon dilution, this yields a working wash solution containing a surfactant in phosphate-buffered saline with a non-azide, non-mercury preservative. The diluted wash solution may be stored at room temperature and is stable until the expiration date on the Insulin ELISA Assay Kit box.

4. ELISA HRP Substrate

One bottle containing **12 mL** of tetramethylbenzidine (TMB) with hydrogen peroxide. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

5. ELISA Stop Solution

One bottle containing **12 mL** of stop solution. This reagent may be stored at 2 – 8°C or room temperature and is stable until the expiration date on the Insulin ELISA Assay Kit box.

6. Human Insulin Standards

Six vials containing recombinant human Insulin in a lyophilized bovine serum-based matrix with a non-azide preservative. **Refer to the vials for exact concentration of the standard.** These standards should be stored at 2 – 8°C and are stable until the expiration date on the kit box. Refer to assay procedure section for reconstitution instructions.

7. Human Insulin Controls

Two vials containing human Insulin in a lyophilized bovine serum based matrix with a non-azide preservative. **Refer to vials for exact concentration range for each control.** Both controls should be stored at 2 – 8°C and are stable until the expiration date on the Insulin ELISA Assay Kit box. Refer to assay procedure section for reconstitution instructions.

SAFETY PRECAUTIONS

The reagents of this Insulin ELISA Assay Kit must be used in professional laboratory. Materials sourced for reagents containing bovine serum was derived in the contiguous 48 United States. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these



reagents as if they are potentially infectious. Avoid contact with reagents containing TMB, hydrogen peroxide, or sulfuric acid. TMB may cause irritation to skin and mucous membranes and cause an allergic skin reaction. TMB is a suspected carcinogen. Sulfuric acid may cause severe irritation on contact with skin. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Use Good Laboratory Practices.

MATERIALS REQUIRED BUT NOT PROVIDED

- Precision single channel pipettes capable of delivering 100 μL .
- Disposable pipette tips suitable for above volume dispensing.
- Aluminum foil.
- Deionized or distilled water.
- Plastic microtiter well cover or polyethylene film.
- ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
- Spectrophotometric microplate reader capable of reading absorbance at 450/650 or 450/620 nm.

SPECIMEN COLLECTION

Serum, EDTA-plasma, and urine samples are suitable specimens for human Insulin measurement. Only **50 μL** of human sample is required for a duplicate determination of human Insulin with this test kit. No special preparation of the individual is necessary prior to specimen collection. Samples should be collected by standard technologies of the clinical laboratory practices and recommended by the manufacturer of sample collection tube. It is extremely important to carefully separate the serum and plasma from blood cells to avoid hemolysis, etc. Serum/EDTA-plasma should be transferred to a clean test tube right after centrifugation. Human samples should be stored at 2 – 8°C if the assay is to be performed within 72 hours. Otherwise, patient samples should be stored at –20°C or below until measurement. Avoid more than three times freeze-thaw cycles of specimen. Do not use hemolyzed, hyperlipemic, heat-treated or any contaminated specimens.

ASSAY PROCEDURE

1. Reagent Preparation

Prior to use allow all reagents to come to room temperature. Reagents from different kit lot numbers should not be combined or interchanged.

- (1) ELISA Wash Concentrate must be diluted to working solution prior to use. Please see REAGENTS section for details.
- (2) Reconstitute assay standards and controls by adding **0.5 mL** of demineralized water to each standard and control bottle. Allow the standards and controls to sit undisturbed for 5 minutes, then mix well by inversions or gentle vortexing. Make sure that all solid is dissolved completely prior to use. These reconstituted standards and controls may be stored at 2- 8°C for up to 3 days or below –20°C for long-term storage. Do not exceed 3 freeze-thaw cycles.



(3) Test Configuration

ROW	STRIP 1	STRIP 2	STRIP 3	STRIP 4
A	STD 1	STD 5	SAMPLE 1	SAMPLE 5
B	STD 1	STD 5	SAMPLE 1	SAMPLE 5
C	STD 2	STD 6	SAMPLE 2	SAMPLE 6
D	STD 2	STD 6	SAMPLE 2	SAMPLE 6
E	STD 3	C 1	SAMPLE 3	
F	STD 3	C 1	SAMPLE 3	
G	STD 4	C 2	SAMPLE 4	
H	STD 4	C 2	SAMPLE 4	

(4) Place a sufficient number of Anti-human Insulin antibody-coated microwell strips in a holder to run human Insulin standards, controls and unknown samples in duplicates.

2. Assay Procedure:

- (1) Add **25 µL** of Standards, Controls and patient samples into the designated microwells.
- (2) Add **100 µL** of the Tracer Antibody to each well.
- (3) Seal the plate wells securely, cover with foil or similar material to protect from light. Incubate the plate shaking, at room temperature for **1 hr. ± 5 minutes**.
- (4) Wash each well 5 times by dispensing 350 µL of working wash solution into each well and then completely aspirating the contents. Alternatively, an automated microplate washer can be used.
- (5) Add **100 µL** of ELISA HRP Substrate into each of the wells.
- (6) Cover the plate with aluminum foil or similar material to avoid exposure to light. Incubate the plate static, at room temperature for **20 minutes**.
- (7) Immediately add 100 µL of ELISA Stop Solution into each of the wells. Mix gently.
- (8) Read the absorbance at 450 nm with reference filter at 620 nm or 650 nm using a 4-parameter curve fitting.

PROCEDURAL NOTES

1. It is recommended that all standards, controls and unknown samples be assayed in duplicate. The average absorbance reading of each duplicate should be used for data reduction and the calculation of results.
2. Keep light-sensitive reagents in the original amber bottles.
3. Store any unused antibody-coated strips in the foil zipper bag with desiccant to protect from moisture.
4. Careful technique and use of properly calibrated pipetting devices are necessary to ensure reproducibility of the test.
5. Incubation times or temperatures other than those stated in this insert may affect the results.
6. Avoid air bubbles in the microwell as this could result in lower binding efficiency and higher CV% of duplicate reading.
7. All reagents should be mixed gently and thoroughly prior to use. Avoid foaming.
8. If adapting this assay to automated ELISA system such as DS-2 (Diamedix Corp., Miami), a procedural validation is necessary if there is any modification of the assay procedure.



INTERPRETATION OF RESULTS

It is recommended to use a 4-parameter standard curve fitting.


1. Calculate the average absorbance for each pair of duplicate test results.
2. Subtract the average absorbance of the level 1 standard (0 ng/mL) from the average absorbance of all other readings to obtain corrected absorbance.
3. The standard curve is generated by the corrected absorbance of all standard levels on the ordinate against the standard concentration on the abscissa using point-to-point or log-log paper. Appropriate computer assisted data reduction programs may also be used for the calculation of results.

The human Insulin concentrations for the controls and the patient samples are read directly from the standard curve using their respective corrected absorbance.

EXAMPLE DATA AND STANDARD CURVE

A typical absorbance data and the resulting standard curve from this Human Insulin ELISA Assay Kit are represented. This curve should not be used in lieu of standard curve run with each assay.

Well I.D.	OD 450/620 nm Absorbance			Results (mIU/L)
	Readings	Average	Corrected	
Std-1: 0 mIU/L	0.004	0.004	0.000	
	0.004			
Std-2: 2.8 mIU/L	0.029	0.029	0.025	
	0.029			
Std-3: 7.9 mIU/L	0.087	0.083	0.079	
	0.079			
Std-4: 23.6 mIU/L	0.381	0.403	0.399	
	0.424			
Std-5: 69 mIU/L	1.792	1.796	1.792	
	1.800			
Std-6: 198 mIU/L	3.247	3.258	3.254	
	3.268			
Control 1	0.185	0.204	0.200	15.5
	0.223			
Control 2	0.863	0.863	0.859	38.1
	0.862			





CONVERSION FACTOR

1 $\mu\text{g/L}$ = 23 mIU/L; 1 mIU/L = 6.0 pmol/L; 1 mIU/L = 43.5 pg/mL

EXPECTED VALUES

Human non-fasting and fasting samples from normal healthy adults ages 20 – 60 were collected and measured with this ELISA. The recommended normal high cut-off for Insulin concentration by using this ELISA is 102.1 mIU/L with an average level of 23.6 mIU/L (range 4.33 – 97.5 mIU/L). We strongly recommend for each laboratory to establish its own normal ranges of fasting and non-fasting population by measuring EDTA plasma and/or serum with this ELISA.

LIMITATION OF THE PROCEDURE

1. An abnormally high Insulin test result cannot be independently used for clinical diagnosis. As with other laboratory tests, a variety of analytical and pre-analytical factors may lead to false high test results. Physicians must interpret the test result in the light of each clinical findings.
2. For sample values reading greater than the highest standard, it is recommended to re-assay samples with further dilutions (i.e. 1:10 or 1:100 with 5%BSA in 0.01M PBS).
3. Water deionized with polyester resins may inactivate the horseradish peroxidase enzyme.

QUALITY CONTROL

To assure the validity of the results each assay should include adequate controls.

PERFORMANCE CHARACTERISTICS

Sensitivity

The analytical sensitivity (LLOD) of the Insulin ELISA as determined by the 95% confidence limit on 16 duplicate determination of zero standard is approximately 0.1928 mIU/L. The LOQ of this test is 0.8789 mIU/L.

High Dose “hook” effect

This assay has showed that it did not have any high dose “hook” for Insulin levels up to 4600 mIU/L.

Specificity

This assay measures human Insulin without any cross-reaction to C-peptide.

Precision

The intra-assay precision was validated by measuring three control samples with 16 replicate determinations.

Sample #	Mean Insulin Value (mIU/L)	CV (%)
1	11.20	7.8
2	44.11	3.1
3	20.2	9.0



The inter-assay precision was validated by measuring two control levels in duplicate in 9 individual assays.

Sample #	Mean Insulin Value (mIU/L)	CV (%)
1	16.56	9.4
2	51.29	8.0

Linearity

Three samples were collected and tested. The results of Insulin percent recovery value in mIU/L are as follows:

	Expected	Observed	Recovery
Level 6	198	-	-
1:2	99	99.363	100%
1:4	49.5	46.992	95%
1:8	24.75	23.953	97%
Level 5	69	-	-
1:2	34.5	28.738	83%
1:4	17.25	17.611	102%
1:8	8.625	9.403	109%
Level 4	23.6	-	-
1:2	11.8	12.121	103%
1:4	5.9	6.64	113%
1:8	2.95	2.872	97%



Spike Recovery

Three samples and three assay standards (7.60, 23 and 69 mIU/L) were combined at equal volumes and tested. The results are as follows:

DILUTION	OBSERVED VALUE (ng/mL)	RECOVERY
Neat A	17.80	-
Std-3: 7.60 mIU/L	12.12	95.4
Std-4: 23.0 mIU/L	17.14	84.0
Std-5: 69.0 mIU/L	37.56	86.5
Neat B	30.12	-
Std-3: 7.60 mIU/L	16.01	84.9
Std-4: 23.0 mIU/L	22.43	84.5
Std-5: 69.0 mIU/L	51.12	103.0
Neat C	10.12	-
Std-3: 7.60 mIU/L	7.36	83.1
Std-4: 23.0 mIU/L	14.05	84.8
Std-5: 69.0 mIU/L	39.03	98.7

REFERENCES

1. Merriam-Webster Dictionary – Definition of insulin.
2. Rudovich NN, Rochlitz HJ, Pfeiffer AF. (2004) Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. *Diabetes* 53:2359-2365
3. Lindstrom T, Hedman CA, Arnquist HJ. (2002). Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs *Diabetes Care* 25:1049-105454
4. Sjostrand M, Gudbjornsdottir S, Holmang A, Lonn L, Strindberg L, Lonnroth P. (2002) Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. *Diabetes* 51:2742-2748
5. Chevenne D., Ruiz J., Lohmann L., et.al.: Immunoradiometric Assay of Human Intact Proinsulin Applied to Patients with Type 2 Diabetes, Impaired Glucose Tolerance, and Hyperandrogenism. *Clinical Chemistry*. 40/5:754, 1994



Warranty Information

Eagle Biosciences, Inc. warrants its Product(s) to operate or perform substantially in conformance with its specifications, as set forth in the accompanying package insert. This warranty is expressly limited to the refund of the price of any defective Product or the replacement of any defective Product with new Product. This warranty applies only when the Buyer gives written notice to the Eagle Biosciences within the expiration period of the Product(s) by the Buyer. In addition, Eagle Biosciences has no obligation to replace Product(s) as result of a) Buyer negligence, fault, or misuse, b) improper use, c) improper storage and handling, d) intentional damage, or e) event of force majeure, acts of God, or accident.

Eagle Biosciences makes no warranties, either expressed or implied, except as provided herein, including without limitation thereof, warranties as to marketability, merchantability, fitness for a particular purpose or use, or non-infringement of any intellectual property rights. In no event shall the company be liable for any indirect, incidental, or consequential damages of any nature, or losses or expenses resulting from any defective product or the use of any product. Product(s) may not be resold, modified, or altered for resale without prior written approval from Eagle Biosciences, Inc.

For further information about this kit, its application or the procedures in this kit, please contact the Technical Service Team at Eagle Biosciences, Inc. at info@eaglebio.com or at 866-411-8023.